Transdermal Delivery of Antihypertensive Agents: A tabular update by Jain, Ashish et al.
International Journal of Drug Delivery 3 (2011) 01-13 
http://www.arjournals.org/ijdd.html 
 
Review 
                                                            
Transdermal Delivery of Antihypertensive Agents: A tabular update ISSN: 0975-0215 
 
Ashish Jain1*,  Anurag Mishra1, Satish Nayak1, Vandana Soni2 
 
*Corresponding author: 
Ashish Jain  
1. Bansal College of Pharmacy, 
Kokta, Anand Nagar, Bhopal-462021, 
India. 
email: 
aashish.pharmatech(at)gmail.com 
Mob No: +91-9981574693 
2. Department of Pharmaceutical 
Sciences, Dr H. S. Gour 
Vishwavidyalaya, Sagar 470003, 
M.P. India 
 
 
Abstract 
Transdermal Drug Delivery System is viable drug delivery 
platform technology and has a strong market world wide. 
Transdermal Drug Delivery System is particularly desirable for 
drugs that need prolonged administration at controlled plasma 
level that basis make appropriateness to antihypertensive agents 
for their transdermal development. Controlled zero order 
absorption, easily termination of drug delivery, easy to 
administration also support for popularity of transdermal delivery. 
This paper reviews the work on transdermal studies of 
antihypertensive agents in the tabular form.     
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Introduction 
The principal of transdermal drug transport is to 
deliver drug across epidermis to achieve systemic 
effect over a prolong period of time. Controlled 
zero order absorption, simple administration 
mode, easy termination in case of failed, 
avoidance of first pass effects, reduction in side 
effects, sustained drug delivery, and improved 
patient compliance make the research interest of 
researchers.  
The first patch of scopolamine approved in 1979, 
and now in the present market there numbers of 
transdermal patches are available for drug such as 
scopolamine, nitroglycerin, nicotin, clonidine, 
fentanyl, estradiol, testosterone, lidocain, and 
oxbutinin. Limited permeability of human skin is 
still a fundamental problem limiting its 
widespread therapeutic use. So it is the very big 
challenge of creating effective transdermal 
system because it involves sufficient drug 
permeability through the stratum corneum.  
 
 
 
 
Furthermore it is also important to ensure that the 
drug delivery systems do not irritate the skin, and  
the drug is not unduly metabolized and delivered 
according to the desired pharmacokinetics and 
pharmacodynamics. [1] 
         The first transdermal drug delivery system was 
bringing forward before 20 years in the United 
States. The technology induced remarkable 
enthusiasm and curiosity in various 
pharmaceutical companies in the 1980s and 90s. 
This curiosity diminished by limitations of the 
existing transdermal technology, and it was found 
that the numbers of drug candidates suitable for 
this route was found to be limited.  
         However thanks to the development of some 
ground-breaking permeation enhancement 
techniques interest in Transdermal Delivery such 
as: 
• The prodrug approach 
• Chemical Potential Adjustment 
• Ionic complex 
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• Eutectic Systems 
• Encapsulting in Liposomes 
• High Velocity particles 
• Lowering of skin resistance by chemicals 
• Microneedle array 
• Abrasing the Skin 
• Phonophoresis, Sonophoresis 
• Electroporation 
• Magnetophoresis 
• Damaging the Stratum corneum by Laser 
radiation 
• Iontophoresis  
 
More than 20 transdermal patches, containing 13 
drug molecules are already available in the 
market. Clonidine, nicotine and glyceryl nitrate 
transdermal products are commercially 
availability. This small group of marketed 
products is representative of many important 
pharmacological classes like antianginal 
(nitroglycerine, isosorbide dinitarte), 
antihypertensive (Clonidine), antiemetics 
(Scopolamine), hormones (estradiol, 
testosterone), urinary antispasmodic (oxybuyrin), 
local anesthetic (lidocaine) and CNS drugs 
(fentanil, nicotine). Many others are in pipeline 
awaiting FDA approval [2]. Some drugs that are 
being extensively investigated for transdermal 
use include albuterol, enalapril, dronabinol, 
ketorlac, alprazolam, cytarabine, atenelol, 
buprenorphine, selegiline, isosorbide dinitrate 
and prozasin. A major breakthrough is expected 
anytime in the form of transdermal insulin. 
Introduction of the physical enhancement 
techniques like iontophoresis combined with the 
prospect of the programmed delivery has 
contributed significantly in the growth of 
transdermal research. Iontophoretic products have 
already been launched in the US market hailing a 
new age programmed transdermal drug delivery 
[3]. Extensive research is going on to develop 
transdermal delivery systems for a wide range of 
drugs. 
 
 
 
Advantages of transdermal drug delivery [4] 
Transdermal Drug Delivery offers several 
important advantages like: 
1.  Transdermal medication delivers a steady 
infusion of a drug over an extended period of 
time. 
2. Adverse effects or therapeutic failures 
frequently associated with intermittent dosing 
can be avoided. 
3. Transdermal delivery can increase the 
therapeutic value of many drugs by         
avoiding specific problems associated with 
the drug e.g., gastro-intestinal irritation, low 
absorption, decomposition due to hepatic 
“first-pass” effect, formation of metabolites 
that cause side effects, short half-life 
necessitating frequent dosing etc. 
4. An equivalent therapeutic effect can be 
elicited via transdermal drug input with a 
lower daily dose of the drug than is necessary, 
if, for example, the drug is given orally. 
5. The simplified medication regimen leads to 
improved patient compliance and reduced 
inter- and intra-patient variability 
6. Self administration is possible with these 
systems. 
7. The drug input can be terminated at any point 
of time by removing transdermal patch. 
8. Transdermal drug delivery can be used as an 
alternative delivery system for patients   
(nauseated or unconscious) who cannot 
tolerate oral dosage forms. 
 
 Limitations of transdermal drug delivery [4] 
 
1.  One of the greatest disadvantages of 
transdermal drug delivery is the possibility 
that a local irritation may develop at the site 
of application.  
2. The drug, the adhesive or other excipients in 
the patch formulation can cause erythema, 
itching, and local edema.  
3. Another significant disadvantage of 
transdermal drug delivery is that the skin’s 
low permeability which limit the number of 
drugs that can be delivered in this manner.  
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4. Many drugs especially drugs with hydrophilic 
structures permeate the skin too slowly to be 
of therapeutic benefit.  
5. The barrier function of the skin changes from one 
site to another on the same person, from person to 
person and also with age.  
 
Selection of drug candidates 
 
 Transdermal route of drug administration has 
certain inherent difficulties that make it 
unsuitable for large number of drugs. The 
selection of suitable of candidates is an important 
step for success of transdermal research. [5] 
 
• Realistically, a transdermal drug delivery 
system should not cover an area more than 50 
Sq.Cms. and hence transdermal drug delivery 
is suitable only for drugs for which the daily 
dose is of the order of a few milligrams. 
• The effective concentration of the drug 
should be low, presumably in the nanogram 
per ml level.  
• The half life (t1/2) of the drug should be short. 
• For drugs having very long biological half-
life, the transdermal route may have little 
extra benefits for the common patients 
(however this route can be beneficial for the 
special patients like preterm infants.) 
• The active ingredients should not have skin 
toxicity. 
• As the diffusion of drug through polymer as 
well as skin is dependent on molecular size, 
the drug of low molecular size is preferred. 
 
 
• The drug should have a low melting point.   
• Drugs, which degrade in the GI tract or/are 
inactivated by hepatic first-pass effect, are 
suitable candidates for transdermal delivery. 
• Tolerance to the drug must not develop under 
the near zero-order release profile of 
transdermal delivery. 
•  Drugs, which have to administer for a long 
period of time or which cause adverse effects 
to non-target tissues can also be formulated 
for transdermal delivery.              
 
Research trends in transdermal and 
antihypertensive agents: 
The main problem associated with the oral drug 
delivery include an uneven bio distribution, lack 
of drug targeting specificity, the necessity of 
large doses to achieve local concentration and 
adverse side effects due to such high dose. Since 
antihypertensives suffer from the disadvantage of 
extensive first pass metabolism and variable 
bioavailability, they are considered ideal 
Transdermal candidates [6].  
 
Various research in this categories so far done are 
summarised below in tabular form: 
S 
No. 
Name of 
Researcher(s)/ 
Year 
Work Title Findings 
1.  Anroop et al 
2009 
Transdermal delivery of 
atenolol:effect of prodrugs 
and iontophoresis 
They were studied  the combined effect of two 
such techniques, iontophoresis and 
esterification, on the transdermal delivery of 
atenolol. Prodrugs significantly enhanced the 
transdermal flux of atenolol in passive process 
while in iontophoresis the enhancement ranged 
from 1.4 to 2.7 fold compared to atenolol. [7] 
2.  Vinay Pandit et al 
2009 
Formulation & evaluation 
of transdermal films for the 
treatment of overactive 
bladder 
That transdermal films are a promising drug 
delivery system for tolterodine tartarate with 
more patient compliance in the treatment of 
overactive bladder. [8] 
3.  Omray et al. 
 
 
3
2008 
Development of mesoph-
asic microreservoir -based 
transdermal drug delivery 
system of propranolol 
The system was also studied for tensile 
strength, moisture content, water vapour 
transmission, drug content,anisotropy & In-
vitro drug release studies. [9] 
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4. Wahid et al 
2008 
Preparation and evaluation 
of transdermal drug delivery 
system of etoricoxib using 
modified chitosan 
Drug free polymeric films of chitosan, 
chemically modified chitosan & blend were 
prepared and evaluated for various 
physiochemical characters. [10] 
5. Gajbhiye et al 
2008 
Dendrimeric 
nanoarchitectures mediated 
transdermal and oral 
delivery of bioactive 
Pulled off ensues from above exploration craft 
our psyche that the dendrimer can be proficiently 
utilized in transdermal and oral drug delivery 
system with immense accomplishment. [11] 
 
6.  Desai et al 
2008 
Effect of enhancers on 
permeation kinetics of 
captopril for transdermal 
system 
Citral and dimethyl formamide as permeation 
enhancers showed the best perm-eability as 
comp-ared to sodium tauroglycolate, sodium 
laurel sulphate. [12] 
7. Jamakandi et al 
2009 
Recent trends in 
transdermal cardiovascular 
therapy 
This article reviews the research on 
cardiovascular patches as well as the marketed 
products. [3] 
8.  Sadashivaiah et al 
2008 
Design and in vitro 
evaluation of haloperidol 
lactate transdermal patches 
containing ethyl cellulose- 
povidone as film formers 
In this study, different ratios of EC and PVP 
transdermal haloperidol lactate patches were 
formulated using 4% hyaluronidase as a 
permeation enhancer. It can be reasonably 
concluded that haloperidol lactate can be 
formulated into transdermal polymeric patches to 
prolong its release characteristics. [13] 
9. Qureshi et al 
2009 
Formulation strategy for 
low absorption window 
antihypertensive agent 
It could be concluded from R2 value for Higuchi 
model and K-Peppas model that release followed 
fickian diffusion mechanism. [14] 
10. Ashish et al 
2009 
A study of transdermal 
delivery of Glibenclamide 
using iontophoresis 
In study we conclude that the Permeation rate of 
drugs across the pigskin can be considerably 
enhanced by the use of iontophoresis. [15] 
11. Gursharanjit et al 
2008 
Screening of vanlafaxine 
hydrochloride for 
transdermal delivery: 
passive diffusion and 
iontophoresis 
In this study researcher group reported  
Iontophoresis increased the permeation rate at 
both concentration levels over their passive 
counterparts, but surprisingly higher steady-state 
flux was obtained from obtained from lower 
donor drug load. [16] 
12. Shinde et al 
2008 
Development and 
characterization of 
transdermal therapeutics 
system of tramadol 
hydrochloride. 
The present work was designed to develop 
suitable transdermal matrix patches of tramadol 
hydrochloride using hydroxy propyl methyl 
cellulose, Eudragit RL-100 and Eudragit RS-100 
with triethyl citrate as a plasticizer and dimethyl 
sulfoxide as a penetration enhancer The batch 
containing Eudragit RL-100 : HPMC (8 : 2) 
showed 79.65% release within 12 h and batch 
containing Eudragit RL-100 : HPMC (2 : 8) 
showed only 58.30% release in 12 h. This is 
because that the Eudragit produce crystallization 
free patch. [17] 
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13. Aqil et al  
2008 
Transdermal therapeutic 
system of enalapril maleate 
using piperidine as penetration 
enhancer 
The optimized formulation was stable with a 
tentative shelf life of two years. Significant fall 
in BP (p<0.001) was observed in experimental 
hypertensive rats which was maintained for 2 
days. There was 3 fold improvement in 
bioavailability with Transdermal  system vis-à-
vis marketed tablet (AUC(0 to t) : 1253.9 
ng.h/ml vs. 422.88 ng.h/ml). These preclinicial 
studies indicate the feasibility of matrix-type 
TTS of EM for 2 day management of 
hypertension. [18] 
14.  Gupta et al 
2007 
Design and development of a 
proniosomal transdermal drug 
delivery system for captopril 
It is evident from this study that the promising 
prolonged delivery system for captopril and has 
reasonably good stability characteristics. [19] 
15. Sunita et al 
2007 
Development of transdermal 
matrix system of captopril 
based on cellulose derivative 
The transdermal delivery system of Captopril 
employing different ratios of polymers, 
ethylcellulose (EC) and hydroxypropyl 
methylcellulose (HPMC) as (3:1) and (2:2) 
were developed. The in vitro skin permeation 
and in vitro dissolution studies showed that 
Captopril release was more in matrices 
containing ratio EC : HPMC as 2:2 compared 
to 3:1. Captopril from matrix containing EC : 
HPMC ratio 2:2 was able to penetrate through 
rabbit abdominal skin. The prepared matrices 
were free from any irritating effect and stable 
for 3 months. [20] 
16.  Trommer et 
al 2006 
Overcoming the stratum 
corneum: The modulation of 
skin permeation 
The progress made mainly over the last decade 
by use of chemical permeation enhancers. [21] 
17. Subal et al 
2006 
Transdermal patches: What 
pharmacists need to know? 
Reduced the side effects and sometimes 
improved the efficacy over other dosage forms. 
[22] 
18.  Aqil et al 
2005 
In-vivo characterization of 
monolithic matrix type 
transdermal drug delivery 
systems of pinacidil 
monohydrate: A technical note 
a single patch application of pinacidil TDDS 
(B-4) can effectively control hypertension in 
rats for two days. The system holds promise for 
clinical studies. [23] 
19. Heather et al 
2005 
Transdermal drug delivery: 
Penetration enhancement 
technique 
Enhancement effects are 
associated with toxicity, therefore limiting their 
clinical application. [24] 
20. Babu et al  
2005 
Effect of penetration enhancers 
on the release and skin 
permeation of bupranolol from 
reservoir-type transdermal 
delivery systems. 
After some time by some researches they made 
a new system for the drug called reservoir. By 
this system they increase the permeation time 
4-5 times more then the desired flux. [25] 
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21 Anroop et al 
2005 
Synthesis and comparative 
skin permeability of 
atenolol and propranolol 
esters. 
In this study Researchers  had used the prodrug 
approach, where atenolol esters were prepared to 
increase its lipophilicity and permeation studies were 
carried out in isolated porcine skin; promising results 
were obtained with caproate ester. [26] 
22. Robert Langer 
2004 
Transdermal drug delivery: 
past progress current status, 
and future prospect 
He suggest skin represents a very important route of 
delivery in that it can provide an destroyed by the liver 
when taken orally. [1] 
23. Lizzy et al  
2004 
Systematic review: 
Antihypertensive drug 
therapy in blank patients 
Drug differ in their efficacy for reducing blood 
pressure in blank patients but there is no solid 
evidence that efficacy for reducing morbidity and 
mortality outcomes differs once patients achieve the 
blood pressure goal. [27] 
24. Grafe et al 
2004 
Carrier mediated 
transport of clonidine in 
human keratinocytes 
In the mechanistic study which performed on the 
human epidermal kiratinocytes cell culture revealed 
that the clonidine transport is affected due to pH. This 
experiment shows the transport of clonidine beyond 
the epidermal layer was affected by the transport of 
tertiary amine and inhibit by the competition with 
other amines such as triptamine,diphenhydramine, 
quinine , guanidine. [28] 
25. Babu et al 
2004 
Effect of cyclodextrins on 
the complexation and 
transdermal delivery of 
bupranolol through rat skin 
Methylated beta-cyclodextrin used as a enhancer, they 
shows the good permeation of the drug. [29] 
26. Cho et al 
2004 
Enhanced transdermal 
delivery of atenolol from 
the ethylene-vinyl acetate 
matrix. 
This study had shown that a matrix system containing 
ethyl vinyl acetate and polyoxy-ethylene 2-oleyl ether 
as penetration enhancers releases the drug in a 
diffusion-controlled manner and is sufficient to cause 
effective permeation. [30] 
27. Zhioxiong et al 
2003 
Novel Transdermal Drug 
Delivery System with 
Polyhydroxyalkanoate and 
Starburst Polyamidoamine 
Dendrimer 
This is the report of the application of PHA and 
dendrimer to the TDDS. [31] 
28. Mohamed et al 
2003 
Matrix type transdermal 
drug delivery system of 
metoprolol tartrate: In-vivo 
characterization 
It was concluded that MT could be administered 
transdermally through the matrix type TDDS 
developed in our laboratory. The drug remained intact 
and stable in the TDDS during storage. [32] 
29. Manvi et al 
2003 
Formulation of transdermal 
drug delivery system of 
ketotifen fumarate 
Concluded that films of eudragit L 100; hydroxyl 
propyl methylcellulose and ethyl cellulose; 
hydroxypropyl methylcellulose polymeric 
combinations may be feasible for formulating rate 
controlled transdermal therapeutic systemof ketotifen 
fumarate for effective control and prophylaxis of 
allergic asthma. [33] 
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 30. Sheree et al 
2003 
Transdermal penetration 
of vasoconstrictors-
present understanding 
and assessment of the 
human epidermal flux 
and retention of free 
bases and ion-pair 
Epidermal retention of VCs and SA did not 
correspond to their molar ratio on application and 
confirmed that following partitioning into the 
stratum corneum, ion-pair separate and penetration 
is vasoconstrictor-transdermal-percutaneous 
absorption-epidermal retention. [34] 
31. Panigrahi et al 
2002 
Formulation and 
evaluation of pseudolatex 
transdermal drug delivery 
system of terbutaline 
sulphate 
The resulted medicated patches were of average 
thickness (95-155 mium), and content uniformity 
of the drug varied from 94.5 to 99.1 percent. [35] 
32. Krishnaiah et al 
2002 
Effect of solvent system 
on the In-Vitro 
permeability of 
nicardipin hydrochloride 
through excised rat 
epidermis 
The use of binary solvent system, ethanol and the 
ratio of 70:30 v/v, is an effective vehiclefor the 
development of a  transdermal therapeutic system 
for nicardipin hydrochloride. [36] 
33. Namdeo et al 
2002 
Liquid crystalline 
pharmacogel based 
enhanced transdermal 
delivery of propranolol 
hydrochloride 
The self maded pharmacogel used in the synthesis 
of prodrugs propranolol palmitate hydrochloride 
and propranolol stearate hydrochloride and carried 
out that the enhancement rate increase 
inflammatory reaction freely done. The lameller 
liquid crystals which present in the gel they get the 
high chemical potency and show the surety of  
drug is given by the precutaneous route 
successfully. [37] 
34. Stamatialis et al  
2002 
Controlled transport of 
timolol maleate through 
artificial membranes 
under passive and 
iontophoretic conditions  
Timolol is also used in the iontophoretic delivery. 
The iontophoretic study mainly used for the 
artificial membranes which have various pore 
sizes. In such studies timolol showes the high 
permeability for microporous membrane, which 
resistant then the skin. [38] 
35. Moroi et al 
2001 
The Pharmacological 
Basis Of Therapeutics 
The timolol (beta-blocker) is normally used in the 
treatment of glaucoma but it belongs to the 
antihypertensive drugs category. [39] 
36. Lennart et al 
1999 
Randomised trial of old 
& new antihypertensive 
drugs in elderly patients: 
Cardiovascular mortality 
& morbidity the Swedish 
trial in old patients with 
Hypertention 
The frequency of congestive 
heart failure was significantly lower in the ACE 
inhibitors 
group than in the calcium antagonists group. [40] 
37 Kirjavainen et al 1999 
Kobayashi et al 2000 
Hirvonen et al 1998 
Stott et al 2001 
Amnuaikit et al 2005 
Skin permeation of 
propranolol from 
polymeric film 
containing terpene 
enhancers for 
transdermal use  
Some other antihypertensive agents have 
hydrophilic-lipophilic nature and they created 
highly expectation. There are the various studies 
have been done on these drugs. These can be used 
as model drugs for transdermal development. [41-
45] 
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38 Kobayashi et al 
1998 
Relationship between the skin 
permeation movement of 
propranolol and skin inflammatory 
reactions. 
The permeability is evaluated by the 
initial studies. That is show drug induces 
inflammatory reactions. [46] 
39 Chesnoy et al 
1998 
Strctural parameters involved in 
the permeation of propanolol HCL 
by iontophoresis and enhancers 
Changes in the electrical and structural 
properties of the stratum cornium after 
incorporation of enhansers. [47] 
40. Pao-Chu Wu et al 
1996 
In vitro percutaneous absorption of 
captopril through excised rabbit 
skin 
The pH dependency in skin permeability 
of zwitterionic drug may reflect the 
permselective property of the skin 
dependent on the lipophilicty. [48] 
41 Ganga et al 
1996 
Effect of azone on the 
iontophoretic transdermal delivery 
of metoprolol tartrate through 
human epidermal in vitro 
It was found that both during passive and 
iontophoresis, azone caused increased 
transport of the drug through the human 
epidermis and transport was increased 
130-fold during iontophoresis compared 
to passive flux. [49] 
42 Thacharodi et al 
1996 
Collagen-chitosan composite 
membranes controlled transdermal 
delivery of nifedipine and 
propranolol hydrochloride 
Some authors made the rate controlling 
device with the help of collagen 
membrane and reports the good 
regulation of drug and controlled release. 
[50] 
43 Thacharodi et al 
1995 
Development and in vitro 
evaluation of chitosan-based 
transdermal drug delivery systems 
for the controlled delivery of 
propranolol hydrochloride  
Regular work helps in the development of 
a suitable delivery system of propanolol. 
Various trials of the polymers (artificial 
or natural) were continuo which helps in 
the development of reservoir and have 
rate controlling property. There was 
developed a gel type reservoir with the 
help of natural polymer “chistone”. Rate-
controlling membranes of varying 
permeability obtained by controlled 
cross-linking with gluteraldehyde were 
also developed using propranolol as 
model drug. [51] 
44 Christine et al 
1992 
Iontrophoretically enhanced 
transdermal delivery of an ACE 
inhibitor in induced hypertensive 
rabbits: Preliminary report 
Both modes of constant-current 
iontophoresis of captopril offer a safe and 
efficacy between the two forms of 
enhanced delivery. [52] 
45 Sclar et al The transdermal patches have better rate 
then the other conventional dosage form. 
This study involving large populations 
were carried out in which transdermal 
dosage form shows better effect 
according to the therapy. [53] 
Utility of a transdermal delivery 
system for antihypertensive 
therapy. Part 1 
1991 
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46 Naline et al Comparative Beta-
adernoceptor blocking 
effects of propanolol, 
bisoprolol, atenolol, 
acebutolol, and diacetolol 
on the human isolated 
bronchus 
It was concluded that:(1) Atenolol & bisoprolol 
were the least potent drugs at bronchial level in 
therapeutic plasma concentration, 
1990 
(2) That test performedon the human isolated 
bronchus might be a useful screening procedur 
for new drugs with potential activity on the 
airways. [54] 
47 Banga et al Iontophoretic delivery of 
drugs: fundamentals, 
development and 
biomedical applications 
This article is intended to review old as well as 
1988 very recent literature on the technique, 
methodology, clinical findings, influencing 
factors, relevant electronics and other related 
aspects of iontophoretic drug delivery, and to 
provide the readers a comprehensive overview 
of the state-of-art of this potential new area of 
biomedical research. [55] 
48 ONeill et al Development and 
evaluation using hairless 
mouse skin of a transdermal 
timolol product   
Maleate ester inhance the gastrointestinal 
1988 solubility so that conventional system carried 
the drug in this form. The free base timolol is 
used in skin permeation studies and which 
system used in this study that is free from base, 
shows and maintained the adequate zero-order 
plasma profile. [56] 
49 Weiss et al Transdermal Controlled 
Systemic Medication 
Clonidine is mostly used in the transdermal 
1987 form because by this form drug avoid first pass 
metabolism. High expectation were as 
pharmacodynamic studies carried out with 
adhesive transdermal patches of the drug 
showed effectiveness comparable to that of  
bupranolol  infusion in rabbits. [57] 
50 Nicholls et al Comparision of transdermal 
nitrate and isosorbide 
dinitrate in chronic stable 
angina 
It is suggested that the dose of TN may have 
been inadequate to demonstrate such an effect 
and further studies using a higher dose 
schedule will be required. [58] 
1986 
51 Wellstien et al  Transdermal delivery of 
bupranolol: 
pharmacodynamics and 
beta-adrenoceptor 
occupancy 
The experimental patch applied to a wider area 
in human volunieer showed that bupranolol 
penetrated in sufficient amounts to have 
pronouncd pharmacological effects against 
isoprenaline-challenged tachycardia. [59] 
1986 
52 Weber et al Clinical experience with 
rate-con- trolled delivery of 
antihypertensive therapy by 
a transdermal system 
The first antihypertensive agent which comes 
in the form of transdermal patch was clonidine. 
The transdermal patch first only evaluated and 
study for clinical efficacy then with the 
combination of diuretic agents. [60] 
1984 
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Conclusion 
Transdermal drug delivery system offer superior 
uniformity of drug concentrations in plasma 
throughout their duration of use. This results in 
reduced side effects and, sometimes, improved 
efficacy over other dosage forms, by the results 
of these  advantages transdermal drug delivery 
system has been become research interest of 
various pharmaceutical industries. But there is 
limitation in Transdermal drug deliver have a 
limited drug candidates due to permeability 
problems. However thanks to the development of 
some ground-breaking permeation enhancement 
techniques, researchers are able to deliver drugs 
having poor permeability. Iontophoresis, 
Sonopphoresis, use of electron beam radiation 
etc, contributed significantly in the growth of 
transdermal research and making hope to develop 
successful Transdermal system even for poor 
candidates. 
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